Document Detail


Neuropeptides and diabetic retinopathy.
MedLine Citation:
PMID:  23043302     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Diabetic retinopathy, a common complication of diabetes, develops in 75% of patients with type 1 and 50% of patients with type 2 diabetes, progressing to legal blindness in about 5%. In the recent years considerable efforts have been put into finding treatments for this condition. It has been discovered that peptidergic mechanisms (neuropeptides and their analogs, activating a diverse array of signal transduction pathways through their multiple receptors) are potentially important in considering drug development strategies. There is a considerable knowledge accumulated over the last three decades on human retinal neuropeptides and those elements in the pathomechanisms of diabetic retinopathy which might be related to peptidergic signal transduction. Human retinal neuropeptides and their receptors will be reviewed along with the theories relevant to the pathogenesis of diabetic retinopathy both in humans and in experimental models. By collating these information the curative potential of certain neupeptides and their analogs/antagonists will also be discussed, along with the already existing clinical treatments of diabetic retinopathy. The most promising peptidergic pathways at which treatment strategies may be developed at present are the stimulation of somatostatin- and pituitary adenylyl cyclase activating polypeptide-related pathways or inhibition of the angiotensinergic mechanisms. Both approaches may result in the inhibition of vascular endothelial growth factor production and neuronal apoptosis, therefore both the optical quality of the image and the processing capability of the neural circuit in the retina may be saved.
Authors:
Robert Gábriel
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-10-9
Journal Detail:
Title:  British journal of clinical pharmacology     Volume:  -     ISSN:  1365-2125     ISO Abbreviation:  Br J Clin Pharmacol     Publication Date:  2012 Oct 
Date Detail:
Created Date:  2012-10-9     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7503323     Medline TA:  Br J Clin Pharmacol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
© 2012 The Author. British Journal of Clinical Pharmacology © 2012 The British Pharmacological Society.
Affiliation:
Department of Experimental Zoology and Neurobiology, University of Pécs, H-7621, Pécs, Ifjusag u. 6. gabriel@gamma.ttk.pte.hu.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The salmonid myostatin gene family: a novel model for investigating mechanisms that influence duplic...
Next Document:  Solid dispersions: a strategy for poorly aqueous soluble drugs and technology updates.